Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

The United States has passed peak obesity, according to new data, suggesting that the sweeping uptake of weight-loss drugs ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

How supplies of GLP-1 drugs could be at risk as a result of the dockworker strike occurring across the East and Gulf coasts: ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. Mounjaro has been on the FDA's shortage ...

Health-care companies fell as one health insurer incurred a rout. Humana shares slid 12% after the health insurer warned that a steep drop in the federal government's quality ratings of its Medicare ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...